Pfizer unveils new R&D structure as Wyeth staff climb aboard
This article was originally published in Scrip
Executive Summary
Pfizer's research operations will be split into two separate organisations following the completion of its $68 billion acquisition of Wyeth. In the sweeping overhaul, the US firm's biopharmaceutical research will be divided into traditional drug discovery, and biotech and vaccines.